ArticleCancer chemotherapy and pharmacology2026
Combination of PARP inhibitor olaparib and a vascular disrupting agent reduces tumor growth in a preclinical model of prostate cancer.
Evangelia Sereti et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.